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IMPORTANCE Surgical treatment comparisons in rare diseases are difficult secondary to the
geographic distribution of patients. Fortunately, emerging technologies offer promise to
reduce these barriers for research.
OBJECTIVE To prospectively compare the outcomes of the 3 most common surgical
approaches for idiopathic subglottic stenosis (iSGS), a rare airway disease.
DESIGN, SETTING, AND PARTICIPANTS In this international, prospective, 3-year multicenter
cohort study, 810 patients with untreated, newly diagnosed, or previously treated iSGS were
enrolled after undergoing a surgical procedure (endoscopic dilation [ED], endoscopic
resection with adjuvant medical therapy [ERMT], or cricotracheal resection [CTR]). Patients
were recruited from clinician practices in the North American Airway Collaborative and an
online iSGS community on Facebook.
MAIN OUTCOMES AND MEASURES The primary end point was days from initial surgical
procedure to recurrent surgical procedure. Secondary end points included quality of life using
the Clinical COPD (chronic obstructive pulmonary disease) Questionnaire (CCQ), Voice
Handicap Index-10 (VHI-10), Eating Assessment Test-10 (EAT-10), the 12-Item Short-Form
Version 2 (SF-12v2), and postoperative complications.
RESULTS Of 810 patients in this cohort, 798 (98.5%) were female and 787 (97.2%) were
white, with a median age of 50 years (interquartile range, 43-58 years). Index surgical
procedures were ED (n = 603; 74.4%), ERMT (n = 121; 14.9%), and CTR (n = 86; 10.6%).
Overall, 185 patients (22.8%) had a recurrent surgical procedure during the 3-year study,
but recurrence differed by modality (CTR, 1 patient [1.2%]; ERMT, 15 [12.4%]; and ED,
169 [28.0%]). Weighted, propensity score–matched, Cox proportional hazards regression
models showed ED was inferior to ERMT (hazard ratio [HR], 3.16; 95% CI, 1.8-5.5). Among
successfully treated patients without recurrence, those treated with CTR had the best CCQ
(0.75 points) and SF-12v2 (54 points) scores and worst VHI-10 score (13 points) 360 days after
enrollment as well as the greatest perioperative risk.
CONCLUSIONS AND RELEVANCE In this cohort study of 810 patients with iSGS, endoscopic
dilation, the most popular surgical approach for iSGS, was associated with a higher recurrence
rate compared with other procedures. Cricotracheal resection offered the most durable
results but showed the greatest perioperative risk and the worst long-term voice outcomes.
Endoscopic resection with medical therapy was associated with better disease control
compared with ED and had minimal association with vocal function. These results may be
used to inform individual patient treatment decision-making.
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T he paradox of rare diseases is that any single diagnosisaffects a small number of individuals, but 6% to 8% ofthe world population is afflicted.1 This fact renders
rare diseases both difficult to study and a significant public
health concern. Even basic epidemiologic studies of rare
diseases are challenging given the heterogeneous, progres-
sive clinical course of the rare disease and the geographic
dispersion of patients.2 Geographic distribution requires an
extensive recruitment and monitoring infrastructure, dra-
matically increasing the cost and time required for partici-
pant accrual. These barriers, coupled with small markets,
reduce incentives for the pharmaceutical industry and
funders to support rare disease research,3 constrain evi-
dence, and result in clinical practice variation and inconsis-
tent patient outcomes.
Fortunately, emerging technologies offer promise
to reduce the barriers to research about rare disease.
Patients have begun to cluster in online communities to
provide mutual support and information about their
conditions.4 These communities have become rich sources
of knowledge about the lived experience of patients with
rare disease.5 Researchers are increasingly interested in
leveraging online communities to rapidly accrue sample
sizes required to generate evidence and improve treatments.
Paralleling this trend are advances in personal mobile com-
puting to generate biomedically relevant data streams,
including self-monitoring of disease symptoms and vital
signs. Patient-generated health data may hold immense
promise to improve treatment outcomes by providing clini-
cians and researchers a view of disease progression at
home.6
Idiopathic subglottic stenosis (iSGS) is a rare,7 recurrent,
and devastating fibroinflammatory disease that leads to
upper airway narrowing and severe dyspnea among adult
white women.8 Because of high recurrence rates, more than
half of patients with iSGS require repeated surgical proce-
dures within 12 months of their initial diagnosis.9 Three
treatments for iSGS predominate,7,10,11 and evidence has
shown variability in outcomes.8,11 This variability has com-
plicated patient decision-making as patients try to balance
survival, symptoms, and quality-of-life considerations.12 We
designed a prospective multicenter observational study
comparing the effectiveness of the 3 most common treat-
ments for iSGS using outcomes that matter most to patients:
time to disease recurrence and treatment quality-of-life
trade-offs. Harnessing emerging technologies, we directly
recruited people with iSGS from an online community on
Facebook in addition to traditional physician-led recruit-
ment efforts. We used a novel approach to monitor treat-
ment response that included clinical data from electronic
health records, longitudinal physiologic data recorded in a
smartphone app, and patient-reported outcome measures.
By coupling patient-generated health data from the digital
platform with clinical data from electronic health records,
the burden of studying rare disease longitudinally across
multiple sites was reduced. This approach facilitated rapid




Adult patients (≥18 years) with untreated, newly diagnosed,
or previously treated iSGS meeting established diagnostic cri-
teria were enrollment candidates.8 Age, sex, and race/
ethnicity were collected based on recorded electronic medi-
cal records and confirmed with the patients. Recruitment of
patients took place from June 1, 2015, to June 1, 2017. Patients
with obstructing subglottic stenosis not attributable to the
2 most common etiologies (granulomatosis with polyangiitis
and intubation-related airway trauma) were included.8
Patients were excluded if their index operative date was
not confirmed or they failed to complete required baseline
surveys. The study was approved by the Vanderbilt Univer-
sity Medical Center institutional review board, Nashville,
Tennessee, and written informed consent was obtained elec-
tronically from each participant.
Setting
Patients were recruited using both traditional and novel meth-
ods with a goal of enrolling 300 participants. The traditional
method involved patient identification and recruitment by cli-
nicians participating in the North American Airway Collabora-
tive (NoAAC) network. The NoAAC consists of 30 participat-
ing tertiary care centers across all regions of the United States
as well as international sites in Australia, France, Iceland,
Norway, and the United Kingdom. All NoAAC sites are refer-
ral centers for iSGS and thus have significant experience treat-
ing this rare disease.7-9,13-15
The novel recruitment method involved direct patient en-
rollment from a community of patients with iSGS on Face-
book. The online community “Living with Idiopathic Subglot-
tic Stenosis” currently has 3030 members (2636 are patients
with iSGS); 42% of members visit the site daily, and 97% visit
at least monthly. The online community has robust leader-
ship, and the founder and chief moderator is a person with iSGS.
Key Points
Question What are the outcomes of the 3 most common surgical
approaches for idiopathic subglottic stenosis (iSGS)?
Findings In this cohort study of 810 patients with iSGS who
underwent 1 of the 3 most common surgical treatments, 23% of
patients underwent a recurrent surgical procedure during the
3-year study period, but recurrence differed by modality
(cricotracheal resection, 1%; endoscopic resection with adjuvant
medical therapy, 12%; and endoscopic dilation, 28%). Among
successfully treated patients, those who underwent cricotracheal
resection reported the highest quality of life but the greatest
perioperative risk and worst long-term voice outcomes.
Meaning These results show the feasibility of integrating an
engaged rare disease community with a network of surgeons to
facilitate rapid and nuanced treatment comparisons; findings may
help inform treatment decision-making in iSGS.
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Her stewardship engenders a positive culture of balanced in-
formation sharing.5 The NoAAC engaged the online commu-
nity leader to solicit her formal involvement in study plan-
ning. In addition to aligning patient and clinician goals, this
integration allowed information (both initial recruiting ef-
forts and continuous project updates) to flow from the leader
to the online community. Weekly conversations between the
leader and principal investigators kept community members
updated on recruitment. Annual in-person study meetings
(with all online community members invited to attend) main-
tained participant engagement. These features allowed study
information to be rapidly disseminated. Interested online com-
munity members with iSGS directly enrolled by contacting the
study coordinator, who obtained permission for medical rec-
ords release and who completed consent for the patients elec-
tronically. Patient information collected from each recruit-
ment method was screened to confirm inclusion criteria and
to allow data entry into the secure electronic data repository.
Study Protocol
Baseline
The study followed the Strengthening the Reporting of Obser-
vational Studies in Epidemiology (STROBE) reporting guideline
and a prespecified protocol (eFigure in the Supplement).16 At
enrollment, patients completed baseline surveys and a series
of patient-reported outcome measures evaluating constructs
affected by the disease and its treatment. In addition, disease-
specific data, a mucosal atopy index, and comorbidity
scores17-21 were abstracted from medical records.
Index Intervention
Each NoAAC center submitted its standard-of-care treatment
algorithm before beginning enrollment. Symptomatic pa-
tients underwent standard-of-care treatment at their respec-
tive medical centers. The index, or most proximate, surgical
procedure (if the last treatment predated study inception) was
defined as time zero (T0).
Primary treatments were endoscopic dilation (ED), endo-
scopic resection with adjuvant medical therapy (ERMT), and
open cricotracheal resection (CTR). All treatments are de-
scribed in detail elsewhere.16 In brief, ED involves using a bal-
loon or rigid bougie to expand the stenotic segment; ERMT uses
a carbon dioxide laser to endoscopically resect quadrants of
the stenotic airway followed by long-term adjuvant medica-
tion (eg, inhaled corticosteroid, a proton pump inhibitor, and
trimethoprim/sulfamethoxazole); and CTR is an open surgi-
cal procedure that involves en bloc removal of the stenotic air-
way followed by anastomosis of the proximal and distal tra-
cheal segments. The study nurse coordinator (C.K.) reviewed
the specifics of the index surgical procedures to confirm the
type of intervention and to ensure adherence to their stan-
dard of care.
Longitudinal Surveillance
Patients completed the electronic health status every 3 months
after enrollment. The electronic data capture system gener-
ated a scheduled, automated query that solicited data on ad-
juvant medication use (eg, inhaled corticosteroids); whether
patients had undergone any interventions to treat their iSGS
(surgical or clinic-based) and, if so, whether they had experi-
enced specific treatment-associated complications; and
patient-reported outcome measures to track symptoms and
quality of life (every 6 months). Reports of treatment or com-
plications triggered notification of the study nurse coordina-
tor, who investigated, verified, and documented these events,
including the date of any recurrent surgical procedure. Pa-
tients were given the ability to self-monitor their disease sta-
tus by daily recording of peak expiratory flow rate (PEFR) using
an inexpensive portable handheld device and a free smart-
phone app designed by the authors.22 The PEFR was mea-
sured in liters per second during a single expiratory cycle and
was reported as percentage of matched normative data
(%PEFR).23,24
Outcomes
The primary end point was need for and time to recurrent
surgical procedure, defined as days from T0 to recurrent
surgical procedure (TR). This end point was derived from
semistructured interviews among patients with iSGS and
participating clinicians, who agreed that it was the most
appropriate surrogate for recurrence.25 Secondary end




Data was analyzed between July 1 and September 30, 2018.
The Kaplan-Meier method assessed time to recurrent surgi-
cal procedure for the 3 primary treatments, and hazard ratios
(HRs) and 95% CIs were calculated using weighted Cox pro-
portional hazards regression models. Censoring occurred with
a recurrent surgical procedure or a patient death. Propensity
score matching and multiple imputation–adjusted HRs were
used for known confounders and missing data (eMethods in
the Supplement). Effect sizes (ESs) and 95% CIs were re-
ported for all comparisons as indicated.
Indication for Recurrent Surgical Procedure
The observational study design precluded prespecifying in-
dications for repeat surgical procedure. In general, the pri-
mary indication for repeat surgical procedure was worsened
breathing; however, the threshold for repeat surgical proce-
dure may differ across centers. Physiologic (%PEFR) and pa-
tient-reported Clinical COPD (chronic obstructive pulmonary
disease) Questionnaire (CCQ) metrics were used to assess
whether this threshold systematically differed by treatment
modality. Loess curves of mixed-effects model–fitted values
for %PEFR assessed the stability of respiratory function for non-
recurring patients.
Results
Recruitment and Study Population
Of the 1056 patients consented, 383 patients (36.3%) were re-
cruited via social media, and 673 (63.7%) were recruited via
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physician referral (Figure 1A). Patient recruitment via social
media outpaced that via physician referral during the first 47
weeks of the 3-year study (Figure 1B). Patients recruited via so-
cial media were slightly younger (mean [SD] age of recruits:
social media, 47 [10] years vs physician referral, 53 [12] years)
but otherwise lacked differences in sociodemographic or base-
line survey completion rates. Given their earlier enrollment in
the study, patients recruited via social media had a longer mean
(SD) follow-up (1.47 [0.88] years vs 1.27 [0.79] years). Overall,
35 patients (3.3%) withdrew from the study, and 211 (20.6%)
consented to participate but were unable to produce treat-
ment data associated with their disease and the index proce-
dure. Exclusions were balanced between Facebook recruits
(71 of 368; 19.3%) and physician referrals (140 of 653; 21.4%).
In all, 810 patients meeting inclusion criteria enrolled, of
whom 798 (98.5%) were female, 787 (97.2%) were white,
and 64.8% (487 of 752 reporting) held college or advanced
degrees, with a median age of 50 years (interquartile range
[IQR], 43-58 years). Index operations were ED (n = 603;
74.4%), ERMT (n = 121; 14.9%), and CTR (n = 86; 10.6%)
(Figure 1A). Anatomically, patients with iSGS presented with
a median (IQR) subglottic narrowing of 11 mm (8-17 mm)
caudal to the vocal folds, median (IQR) craniocaudal length
of 15 mm (10-20 mm), and median (IQR) airway obstruction
at T0 of 60% (50%-75%).
Patient sociodemographic and clinical characteristics
were similar across treatment modalities (Table). Patients
who underwent ERMT were predominantly white (121 of 121;
100%), older (median, 56 years; range, 48-63 years), and had
greater median percentage of luminal obstruction at T0
(75%; range, 64%-80%). Patients who underwent ED
showed the shortest median segment of subglottal narrow-
ing (12 mm; range, 10-17 mm). Stenosis observed in this
group was the farthest from the vocal folds (15 mm; range,
10-20 mm). Patients who underwent ERMT experienced the
longest median duration of disease (8.6 years; IQR, 3.4-13.0
years), and patients who underwent CTR had the most surgi-
cal procedures (n = 5) performed before open reconstruction
at T0 (range, 3-7 surgical procedures).
Time to Recurrence (Primary End Point)
Median (IQR) follow-up after T0 was similar between patients
who underwent ED (1.3 [0.4-2.2] years) vs those who under-
went ERMT (1.5 [0.2-3.6] years) and was significantly longer
for patients who underwent CTR (4.3 [1.7-6.1] years) (Table).
Overall, 185 patients (22.8%) had a recurrent surgical proce-
dure during the 3-year study period, but the rate differed across
modalities. Open cricotracheal resection had a 1.2% recur-
rence rate (1 of 86 patients), followed by 12.4% (15 of 121) for
ERMT and 28.0% (169 of 603) for ED. Kaplan-Meier analysis
Figure 1. Flowchart and Absolute Number of Participants Recruited
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showed the need for and the time to recurrent surgical proce-
dure between treatment modalities (Figure 2). With 1 recur-
rence within the CTR group, only ED and ERMT were compa-
rable (ERMT vs ED: HR, 3.03; 95% CI, 1.78-5.17). Propensity
score matching was used to minimize bias from nonrandom-
ized treatment assignment. Weighted Cox proportional haz-
Table. Characteristics of Patients With Idiopathic Subglottic Stenosis
Characteristic ED (n = 603) ERMT (n = 121) CTR (n = 86) Total (N = 810) Effect Sizea Test Typeb
Age at index procedure, median (IQR), y 49 (42-57) 56 (48-63) 48 (39-55) 50 (43-58) 0.036 (0.015-0.063) 1
Female, No. (%) 593 (98.3) 121 (100) 84 (97.5) 798 (98.5) 0.032 (0-0.089) 2
Married, No. (%)c 426 (76.1) 86 (76.1) 70 (86.4) 582 (77.2) 0.076 (0-0.141) 2
White race, No. (%) 580 (95.9) 121 (100) 86 (100) 787 (97.2) 0.105 (0.017-0.171) 2
White (non-Hispanic or Latino) ethnicity, No. (%)c 503 (97.4) 87 (100) 60 (93.8) 650 (97.5) 0.089 (0-0.159) 2
Educational level, No. (%)c
Graduate school 153 (27.4) 22 (19.5) 14 (17.3) 189 (25.1)
0.092 (0-0.127) 2
College graduate 218 (39.0) 42 (37.2) 38 (46.9) 298 (39.6)
Some college 118 (21.0) 34 (30.1) 23 (28.4) 175 (23.3)
High school or less 70 (12.5) 15 (13.3) 5 (6.2) 90 (12.0)
Stenosis, median (IQR), % 50 (40-70) 75 (64-80) 60 (60-70) 60 (50-75) 0.06 (0.034-0.088) 1
Stenosis length, median (IQR), mm 12 (10-17) 15 (10-20) 17 (15-20) 15 (10-20) 0.02 (0.005-0.042) 1
Distance below glottis, median (IQR), mm 15 (10-20) 10 (5-15) 10 (5-15) 11 (8-17) 0.018 (0.005-0.04) 1
Disease duration, median (IQR), y 5.5 (2.5-9.9) 8.6 (3.4-13.0) 6.1 (3.9-10.2) 5.8 (2.6-10.7) 0.014 (0.002-0.034) 1
Surgical procedure, No. (range) 3 (2-7) 3 (2-6) 5 (3-7) 3 (2-7) 0.015 (0.004-0.031) 1
Charlson Comorbidity Index, median (IQR) 0 0 0 0 0.007 (0-0.018) 1
Gastroesophageal reflux disease, No. (%)c 206 (37.1) 43 (38.4) 31 (38.8) 280 (37.5) 0.013 (0-0.05) 2
Premenopausal, No. (%)c 204 (72.6) 20 (64.5) 25 (71.4) 249 (72.0) 0.051 (0-0.138) 2
Hormone replacement therapy, No. (%)c 5 (1.8) 1 (3.2) 0 6 (1.7) 0.054 (0-0.143) 2
Full-term pregnancy, No. (%)
0 139 (25.3) 12 (10.9) 13 (16.5) 164 (22.2)
0.123 (0.041-0.157) 2
1 81 (14.7) 10 (9.1) 7 (8.9) 98 (13.3)
2 203 (36.9) 51 (46.4) 35 (43.8) 289 (39.1)
3 88 (16.0) 22 (20.0) 16 (20.0) 126 (17.1)
>3 39 (7.1) 15 (13.6) 8 (10.0) 62 (8.4)
Years of follow-up, median (IQR), y 1.3 (0.4-2.2) 1.5 (0.2-3.6) 4.3 (1.7-6.1) 1.4 (0.4-2.5) 0.011 (0.002-0.024) 1
Abbreviations: CTR, cricotracheal resection; ED, endoscopic dilation; ERMT,
endoscopic resection with adjuvant medical therapy; IQR, interquartile range.
a Epsilon-squared for Kruskal-Wallis test and Cramer V for Pearson χ2 test.
The 95% CIs for epsilon-squared values are estimated by adjusted bootstrap
percentile (bias-corrected and accelerated) interval with 1000 replications;
95% CIs for Cramer V values are estimated by noncentral χ2.
b Test type: 1, Kruskal-Wallis test; 2, Pearson χ2 test.
c Not reported for all participants.
Figure 2. Kaplan-Meier Analysis of Disease Recurrence Among the 3 Treatment Groups
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ards regression models (eTable 1 in the Supplement) showed
that ED was inferior compared with ERMT (HR, 2.77; 95% CI,
1.4-5.5), and this association persisted in propensity score–
matching models accounting for missing data (ED vs ERMT:
HR, 3.16; 95% CI, 1.82-5.51) (eTable 2 in the Supplement).
Indication for Recurrent Operation
In all, 496 (61.2%) patients recorded PEFR (ED: 383 [63.5%];
ERMT: 62 [51.2%]; and CTR: 51 [59.3%]); the only difference
between reporters and nonreporters was that nonreporters
were older at 52 years (95% CI, 43-59 years) vs 49 years
(95% CI, 42-56 years). No difference in median %PEFR or CCQ
score in the ED and ERMT groups was observed before recur-
rent surgical procedure (%PEFR: ED, 56.5% [IQR, 44%-69%]
vs ERMT, 54% [IQR, 45%-59%] and CCQ: ED, 2.4 [IQR 1.6-3.4]
vs ERMT, 2.6 [IQR, 1.6-3.3]). Thus, a similar threshold for re-
peat surgical procedure was exercised across modalities. Loess
curves of mixed-effects model–fitted values for %PEFR con-
firmed that successfully treated patients without recurrence
had stable respiratory function (Figure 3).
Patient-Reported Outcome Measures
Breathing
Among patients who were successfully treated (ie, did not re-
cur during the study period), those who underwent CTR had
the best CCQ scores at 360 days after enrollment followed by
those who underwent ERMT and ED treatment (ED, 1.80 vs
ERMT, 1.25 vs CTR, 0.75). Treatment with CTR was associ-
ated with statistically and clinically better breathing at 360 days
compared with either ERMT or ED (CTR vs ERMT: ES, 0.3;
95% CI, 0-0.8; CTR vs ED: ES, 0.8; 95% CI, 0.4-1.3). Treat-
ment with ERMT showed better breathing outcomes com-
pared with treatment using ED (ERMT vs ED: ES, 0.5; 95% CI,
0.1-0.8) (Figure 4A).
Voice and Swallowing
Outcomes among successfully treated patients differed 360
days after enrollment. In contrast with breathing, Voice Handi-
cap Index-10 scores of patients who underwent CTR were both
statistically and clinically worse compared with scores for pa-
tients who underwent ERMT (CTR, 13.0 vs ERMT, 3.5; ES, 6;
95% CI, 1.0-10.0) but not different compared with ED (CTR, 13.0
vs ED, 10.0; P = .07). Patients who underwent ED had worse
scores compared with those who underwent ERMT (ED, 10.0
vs ERMT, 3.5; ES, 3; 95% CI, 0-6.0) (Figure 4B). The associa-
tion with swallowing was minimal among all treatment groups,
and although statistical differences were observed, no Eating
Assessment Test-10 scores met the threshold to be consid-
ered clinically abnormal (all median scores <3)20 (Figure 4C).
Global Physical Health
At 360 days, patients who underwent ED had lower median
12-Item Short-Form Version 2 scores compared with patients
who underwent ERMT (ED, 49 vs ERMT, 53; ES, 2.3; 95% CI,
−5.66 to 0.55) or CTR (ED, 49 vs CTR, 54; ES, 3.1; 95% CI, −6.9
to 0.29). These outcomes may suggest that global quality of
life is statistically and clinically worse after treatment with ED
compared with treatment of either ERMT or CTR (Figure 4D).
Perioperative Complications and Death
Cricotracheal resection was associated with a number of com-
plications. In order of incidence, 8 of 86 patients (9.3%) re-
quired a temporary tracheostomy or T-tube and 8 (9.3%) re-
quired an unplanned return to the operating room during their
initial hospitalization. Moreover, 7 patients (8.1%) developed
a permanent unilateral vocal fold paralysis, and 3 (3.5%) had
Figure 3. Longitudinal Mean Peak Expiratory Flow Rate
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Loess smooth curve of mixed-effects model shows sustained peak expiratory
flow rate (measured in liters per second during a single expiratory cycle and
reported as percentage of matched normative data) among patients after
successful treatment. Self-reported patient longitudinal peak expiratory flow
rate was captured using an inexpensive portable handheld device and a free
smartphone app created specifically for this study.
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an anastomotic leak. Less common complications included per-
manent bilateral vocal fold paralysis in 1 patient (1.2%), urinary
tract infections secondary to an indwelling catheter in 1 pa-
tient (1.2%), and postoperative pneumonia in 1 patient (1.2%).
Endoscopic resection with adjuvant medical therapy was
associated with adverse events during the surgical procedure
and the postoperative medical regimen. In order of inci-
dence, perioperative issues included 14 patients (11.6%) who
developed temporary (≤4 weeks) tongue paresthesia associ-
ated with direct laryngoscopy and 4 patients (3.3%) who had
a dental injury. Overall, 35 patients (28.9%) had an adverse re-
action to trimethoprim/sulfamethoxazole received postop-
eratively, with 27 (22.3%) stopping the medication because of
rash, nausea, or fever.
Endoscopic dilation had a similar perioperative adverse
event profile compared with ERMT. These similarities in-
cluded 84 of 603 patients (13.9%) who had temporary tongue
paresthesia, 34 (5.6%) who had a dental injury, and 3 (0.5%)
who had transient postoperative subcutaneous emphysema.
All occurrences of subcutaneous emphysema resolved with
conservative management. Of 810 patients, 3 died (0.04%):
1 in the ERMT group and 2 in the ED group. Death was second-
ary to airway obstruction more than 30 days after the surgi-
cal procedure.
Discussion
Idiopathic subglottic stenosis is a recurrent, rare (1:400,000)7
fibroinflammatory disease that results in life-threatening
blockage of the upper airway. Harnessing an engaged online
community of patients coupled with innovative digital tools,
we rapidly recruited a cohort of 810 patients with iSGS to com-
pare the effectiveness of contemporary treatments with re-
current surgical procedure while assessing quality of life and
perioperative risk trade-offs.
Treatment effectiveness at recurrent surgical procedures
and risk trade-offs differed by modality. Patients who
underwent CTR had the lowest rate of recurrent surgical
procedure (1.2%), followed by ERMT (12.4%) and ED
(28.0%). Considering disease recurrence in the context of treat-
ment trade-offs, CTR was associated with the greatest peri-
operative risk and the worst postoperative patient-reported
voice outcomes. Regarding disease recurrence rate, ERMT
was at a 15.6% lower rate compared with ED (the present
standard-of-care treatment). Both endoscopic procedures
(ERMT and ED) had a similar low rate of perioperative risks
and modest differences in patient-reported breathing,
voice, and quality-of-life score changes compared with CTR.
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Swallowing complaints were uncommon regardless of treat-
ment modality.
Treatment Advantages and Trade-offs
Cricotracheal Resection
Our results are consistent with published single-center series
documenting excellent surgical procedure outcomes after
CTR.26 The disease recurrence rate after ERMT also parallels
a retrospective analysis.11 Interestingly, published case series
reported that 80% of patients had recurrent stenosis after un-
dergoing ED within 1000 days of the initial surgical procedure.11
This result is a significantly higher rate than we observed in
our study (28.0%). This disparity may stem from our inclu-
sion of patients from centers of excellence and from smaller
centers recruited online. Previous retrospective studies re-
ported outcomes from high-volume centers with patients who
have recalcitrant disease cluster, which may explain a higher
disease recurrence rate.
Although our results appear to support the effectiveness
and durability of CTR, they must be interpreted in context.
First, not all patients were candidates for CTR because a suf-
ficient distance below the vocal folds was required to per-
form this surgical procedure. Second, previous reports iden-
tified a significant rate of recurrent disease (10%-30%) among
patients who underwent CTR that occurred from 5 to 10 years
after the surgical procedure.26-28 These outcomes were not ob-
served in our cohort given the temporal scope of our study.
Longer-term follow-up of patients who underwent CTR from
our cohort will continue to address this question. Although re-
ports of patient complications after CTR are variable within the
literature, our data appeared comparable with the reported 10%
to 20% rate of anastomotic complications26-29 and 5% to 10%
rate of postoperative unilateral vocal fold paralysis.26,27
Endoscopic Treatments
A notable outcome of our study was the findings for ERMT. In
this 3-year study, ERMT offered significantly improved disease
control compared with ED (the most common treatment) with
minimal association with voice function, particularly when com-
pared with CTR. Whether the reduced disease recurrence rate
for ERMT was associated with surgical technique, postoperative
medications, or a combination remains unclear. Moreover,
whether ERMT outcomes will converge with ED during a longer
follow-up is an area of continued study in our cohort.
Effectiveness of Novel Recruitment Strategy
For studies of rare disease, recruiting enough participants is
challenging. Among clinical trials, 10% of investigators fail to
recruit a single patient, and fewer than 20% of trials finish on
time because of poor recruitment.30 Social media recruit-
ment provides the ability to target a relevant and engaged au-
dience of patients and allows for direct communication with
participants. Although the issue of data privacy surrounding
social media is clearly a salient topic, our study obtained no
data from social media (ie, no content from social media pro-
files was queried or collected). We simply leveraged an on-
line community of patients housed in social media for recruit-
ment and to sustain patient engagement. Our ability to more
than double our enrollment goal (target of 300 patients and
actual recruitment of 810 patients) was a testament to the ef-
fectiveness of including a social media recruitment strategy.
In our study, we believe this protocol promoted a deep sense
of patient ownership in the study process and dramatically lim-
ited attrition (n = 35; 3.3%).
Limitations
This study is not without limitations. Because of the nonran-
dom treatment assignment, unmeasured confounding vari-
ables may have affected the surgical outcomes. Additionally,
given the individualized nature of surgical therapy, issues of
generalizability exist in our results. CTR requires special train-
ing, experience, and institutional infrastructure, which lim-
its the generalizability of our findings. The degree to which out-
comes in our cohort for CTR are transferable between centers
requires further study. Despite its advantages, ERMT was per-
formed at only 1 institution and involved several intraopera-
tive techniques that differed substantially from how most sur-
geons endoscopically treat iSGS. In addition, the postoperative
medical regimen was complex. These factors may affect the
generalizability of the results.
Conclusions
We leveraged an engaged patient community on social media
and collected patient-generated health data to study the natu-
ral history and outcomes of a rare airway disease. Our ap-
proach allowed nuanced comparison of the effectiveness of sur-
gical treatments for iSGS. The most popular approach (ED) was
associated with higher rates of recurrence compared with al-
ternative treatments. Cricotracheal resection offered the most
durable results but showed the greatest perioperative risk and
worst long-term voice outcomes. Endoscopic resection with
adjuvant medical therapy was associated with better disease
control compared with ED, with minimal association with voic-
ing. These results may be used to inform individual patient
treatment decision-making and show the feasibility and ef-
fectiveness of integrating social media–based recruitment and
patient-generated health data to drive the study of iSGS and
other rare diseases.
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